Mitsubishi Tanabe's 2M-unit recall follows QC lapse

A QC lapse has led Mitsubishi Tanabe Pharma to recall 2 million doses of three parenterals. The company says that for certain lots of the products, some aspects of pre-ship testing didn't make the grade.

The Osaka-based drugmaker says that it conducted quality testing of retention samples from its Ashikaga plant, north of Tokyo, and found no quality problems. Bloomberg reports that a male employee in his 40s failed to complete some quality-control tests. The worker has been replaced and production has resumed.

Among the recalled products are specific dosage forms of erectile-dysfunction drugs alprostadil and Prostaglandin E1, anti-inflammatory limethason, a synthetic adrenocortical hormone, and an anti-bacterial.

For Mitsubishi, it's at least the second recall in two years, Bloomberg says. The drugmaker recalled a blood-plasma product in 2009 because of manipulated data.

- see the Mitsubishi announcement
- here's the article

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.